{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:03:53Z","timestamp":1789009433255,"version":"build-2803163510"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T00:00:00Z","timestamp":1434931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert hematopathologists improves accuracy of subtyping, and referral to academic or specialty centers is recommended. Many patients, however, will receive treatment in the community, and knowledge of approved agents is key to optimizing therapeutic approaches for all patients. There is no current standard of care for patients with PTCL and no approved therapies for first-line treatment. Although many patients initially respond to induction chemotherapy, responses are often brief, and many patients relapse or become treatment refractory. For patients with relapsed or refractory PTCL, achievement of durable responses is challenging, and there are few treatment options. Romidepsin is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received one prior systemic therapy or more and patients with PTCL who have received one prior therapy or more. Approval of romidepsin for PTCL was based on a pivotal phase II study of patients with relapsed or refractory PTCL (n = 131) that demonstrated an objective response rate of 25% including 15% with complete response; responses lasted a median of &amp;gt;2 years. Long-term responses to romidepsin were achieved in patients regardless of baseline characteristics, including subtype, heavy pretreatment, response to prior therapy, or advanced disease. Common adverse events included hematologic abnormalities, gastrointestinal or asthenic conditions, and infections; romidepsin was not correlated with clinically meaningful QT prolongation or electrocardiogram abnormalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice:<\/jats:title>\n                  <jats:p>Due to the rarity, severity, and heterogeneous nature of peripheral T-cell lymphoma (PTCL), diagnosis by expert hematopathologists is preferred, and referral to specialty centers is recommended. Many patients, however, will receive treatment in the community, and community oncologists play a key role in the recognition and treatment of PTCL. Knowledge of approved agents is key for optimizing therapeutic approaches. This review provides an overview of PTCL and an in-depth examination of romidepsin, a histone deacetylase inhibitor approved for the treatment of relapsed or refractory PTCL, and highlights difficulties of diagnosis and optimization of treatment modalities for patients with PTCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0043","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T01:21:10Z","timestamp":1435022470000},"page":"1084-1091","source":"Crossref","is-referenced-by-count":74,"title":["Romidepsin for the Treatment of Peripheral T-Cell Lymphoma"],"prefix":"10.1093","volume":"20","author":[{"given":"Swaminathan P.","family":"Iyer","sequence":"first","affiliation":[{"name":"Houston Methodist Cancer Center;, Houston, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine F.","family":"Foss","sequence":"additional","affiliation":[{"name":"Yale Cancer Center;, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,6,22]]},"reference":[{"key":"2021122309363220200_B1","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"2021122309363220200_B2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CCO.0b013e3282ce6f8f","article-title":"Management of peripheral T-cell non-Hodgkin's lymphoma","volume":"19","author":"Horwitz","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"2021122309363220200_B4","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood.V120.21.1611.1611","article-title":"The outcome of T-cell lymphoma patients failing first-line treatment: Results of a population based-study from the Modena cancer registry","volume":"120","author":"Biasoli","year":"2012","journal-title":"Blood"},{"key":"2021122309363220200_B5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V120.21.1614.1614","article-title":"Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): First detailed report of primary treatment","volume":"120","author":"Foss","year":"2012","journal-title":"Blood"},{"key":"2021122309363220200_B6","volume-title":"Cancer facts & figures 2015"},{"key":"2021122309363220200_B7","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood.V120.21.4264.4264","article-title":"Trends in incidence and outcome in T-cell lymphoma since 1992: A SEER database analysis","volume":"120","author":"Petrich","year":"2012","journal-title":"Blood"},{"key":"2021122309363220200_B8","volume-title":"Peripheral T-cell lymphoma facts"},{"key":"2021122309363220200_B9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/PAS.0000000000000188","article-title":"Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T\/NK-cell lymphomas. A North American PTCL study group project","volume":"38","author":"Hsi","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"2021122309363220200_B10","volume-title":"NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's lymphoma, V.2.2015"},{"key":"2021122309363220200_B11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23144","article-title":"The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Armitage","year":"2012","journal-title":"Am J Hematol"},{"key":"2021122309363220200_B12","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"2021122309363220200_B13","doi-asserted-by":"crossref","first-page":"624040","DOI":"10.1155\/2010\/624040","article-title":"Peripheral T-cell lymphoma: Review and updates of current management strategies","volume":"2010","author":"Tang","year":"2010","journal-title":"Adv Hematol"},{"key":"2021122309363220200_B14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122309363220200_B15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122309363220200_B16","first-page":"336","article-title":"HTLV-1 and associated adult T-cell leukemia\/lymphoma","volume":"7","author":"Mahieux","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"2021122309363220200_B17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000478-199601000-00012","article-title":"Report of the workshop on nasal and related extranodal angiocentric T\/natural killer cell lymphomas. definitions, differential diagnosis, and epidemiology","volume":"20","author":"Jaffe","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"2021122309363220200_B18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/asheducation-2011.1.336","article-title":"Tricky and terrible T-cell tumors: These are thrilling times for testing: Molecular pathology of peripheral T-cell lymphomas","volume":"2011","author":"De Leval","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122309363220200_B19","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"2021122309363220200_B20","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"2021122309363220200_B21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122309363220200_B22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"2021122309363220200_B24","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021122309363220200_B26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodr\u00edguez","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122309363220200_B27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2013.08.016","article-title":"Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation","volume":"89","author":"Gkotzamanidou","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122309363220200_B28","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","article-title":"Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas","volume":"2010","author":"Reimer","year":"2010","journal-title":"Adv Hematol"},{"key":"2021122309363220200_B29","volume-title":"Istodax [package insert]","year":"2014"},{"key":"2021122309363220200_B30","volume-title":"Beleodaq [package insert]","year":"2014"},{"key":"2021122309363220200_B31","volume-title":"Folotyn [package insert]","year":"2012"},{"key":"2021122309363220200_B32","volume-title":"Adcetris [package insert]","year":"2013"},{"key":"2021122309363220200_B33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2021122309363220200_B34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"2021122309363220200_B35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4161\/epi.3.3.6253","article-title":"A work in progress: The clinical development of histone deacetylase inhibitors","volume":"3","author":"Marsoni","year":"2008","journal-title":"Epigenetics"},{"key":"2021122309363220200_B36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: Can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol Oncol"},{"key":"2021122309363220200_B37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"key":"2021122309363220200_B38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J Hematol Oncol"},{"key":"2021122309363220200_B39","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res"},{"key":"2021122309363220200_B40","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1345\/aph.1C510","article-title":"Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists","volume":"37","author":"Navari","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2021122309363220200_B42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1634\/theoncologist.7-1-65","article-title":"The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: Is there cause for concern?","volume":"7","author":"Keefe","year":"2002","journal-title":"The Oncologist"},{"key":"2021122309363220200_B43","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"2021122309363220200_B44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1359-4117.2002.01039.x","article-title":"A phase I trial of depsipeptide (FR901228) in patients with advanced cancer","volume":"2","author":"Marshall","year":"2002","journal-title":"J Exp Ther Oncol"},{"key":"2021122309363220200_B45","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B46","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"2021122309363220200_B47","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood.V122.21.4385.4385","article-title":"Romidepsin is effective and well-tolerated in patients \u2265 60 years old with relapsed or refractory peripherl T-cell lymphoma (PTCL): Analysis from phase 2 trials","volume":"122","author":"Shustov","year":"2013","journal-title":"Blood"},{"key":"2021122309363220200_B48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2021122309363220200_B50","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood.V124.21.1742.1742","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL)","volume":"124","author":"Pro","year":"2014","journal-title":"Blood"},{"key":"2021122309363220200_B51","article-title":"Clinical benefit of prolonged stable disease in patients with peripheral T-cell lymphoma (PTCL) treated with romidepsin","volume-title":"Poster presented at: 2014 T-Cell Lymphoma Forum","author":"Foss","year":"2014"},{"key":"2021122309363220200_B52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","article-title":"Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma","volume":"2","author":"Foss","year":"2014","journal-title":"Biomark Res"},{"key":"2021122309363220200_B53","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclosphosphamide, doxorubicin, vinrcristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: A non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"suppl","key":"2021122309363220200_B54","doi-asserted-by":"crossref","first-page":"TPS8616a","DOI":"10.1200\/jco.2013.31.15_suppl.tps8616","article-title":"ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma","volume":"31","author":"Delarue","year":"2013","journal-title":"J Clin Oncol"},{"issue":"(suppl 1)","key":"2021122309363220200_B55","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3816\/CLC.2005.s.004","article-title":"Histone deacetylase inhibitors: Emerging anticancer therapeutic agents?","volume":"7","author":"Kristeleit","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"2021122309363220200_B56","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-06-1715","article-title":"HDAC inhibitors and cardiac safety","volume":"13","author":"Molife","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B57","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.1158\/1078-0432.CCR-08-0376","article-title":"Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors","volume":"14","author":"De Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6605726","article-title":"A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and\/or paclitaxel in patients with solid tumours","volume":"103","author":"Lassen","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122309363220200_B59","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B60","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","article-title":"A phase II study of depsipeptide in refractory metastatic renal cell cancer","volume":"5","author":"Stadler","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"2021122309363220200_B62","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309363220200_B63","doi-asserted-by":"crossref","first-page":"3106a","DOI":"10.1200\/jco.2005.23.16_suppl.3106","article-title":"Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies","volume":"23","author":"Fischer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B64","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B65","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","article-title":"Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel","volume":"19","author":"Noonan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309363220200_B66","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.467","article-title":"Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin","volume-title":"Cancer Med","author":"Sager","year":"2015"},{"key":"2021122309363220200_B67","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood.V114.22.3709.3709","article-title":"Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin","volume":"114","author":"Cabell","year":"2009","journal-title":"Blood"},{"key":"2021122309363220200_B68","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00520-011-1348-9","article-title":"Acute effect of palonosetron on electrocardiographic parameters in cancer patients: A prospective study","volume":"20","author":"Yavas","year":"2012","journal-title":"Support Care Cancer"},{"key":"2021122309363220200_B69","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00520-011-1226-5","article-title":"Electrocardiographic findings of palonosetron in cancer patients","volume":"20","author":"Gonullu","year":"2012","journal-title":"Support Care Cancer"},{"key":"2021122309363220200_B70","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428190290026367","article-title":"Hypomagnesemia and hypocalcemia in mycosis fungoides: A retrospective case series","volume":"43","author":"Morgan","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2021122309363220200_B71","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2010.06.012","article-title":"Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study","volume":"160","author":"Peacock","year":"2010","journal-title":"Am Heart J"},{"key":"2021122309363220200_B72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3945\/ajcn.112.053132","article-title":"Circulating and dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective studies","volume":"98","author":"Del Gobbo","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"2021122309363220200_B73","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfm730","article-title":"Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal","volume":"23","author":"Santoro","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2021122309363220200_B74","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1472-8206.2010.00835.x","article-title":"Mechanisms of hypokalemia-induced ventricular arrhythmogenicity","volume":"24","author":"Osadchii","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"2021122309363220200_B75","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/cncr.28676","article-title":"Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network","volume":"120","author":"Herrera","year":"2014","journal-title":"Cancer"},{"key":"2021122309363220200_B76","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1182\/blood.V120.21.4263.4263","article-title":"Biomarker quality assurance (QA) findings from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) registry","volume":"120","author":"Hsi","year":"2012","journal-title":"Blood"},{"key":"2021122309363220200_B77","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: Results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309363220200_B78","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood.V120.21.1607.1607","article-title":"Angioimmunoblastic T-cell lymphoma (AITL) is the most prevalent T-cell lymphoma entity in Western Europe","volume":"120","author":"Parrens","year":"2012","journal-title":"Blood"},{"key":"2021122309363220200_B79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood.V120.21.298.298","article-title":"Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations","volume":"120","author":"Yoshida","year":"2012","journal-title":"Blood"},{"key":"2021122309363220200_B80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-08-1808","article-title":"Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia\/lymphoma","volume":"15","author":"Nakagawa","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2021122309363220200_B81","doi-asserted-by":"crossref","first-page":"e17570a","DOI":"10.1200\/jco.2013.31.15_suppl.e17570","article-title":"Medical oncologists\u2019 clinical experiences and comfort levels with 20 recently approved agents","volume":"31","author":"Love","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0043","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/9\/1084\/41869683\/oncolo_20_9_1084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/9\/1084\/41869683\/oncolo_20_9_1084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:34:09Z","timestamp":1640316849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/9\/1084\/6399657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,22]]},"references-count":81,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,6,22]]},"published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0043","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,9,1]]},"published":{"date-parts":[[2015,6,22]]}}}